Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurological Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PPP5C drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | PPP5C Recombinant Protein, high purity (>95%), Endotoxin <1EU/ug, Sequence Verified. | View PPP5C Products |
| Mutant Panel | PPP5C Mutant Recombinant Proteins (catalytic site variants H304A, H352A) for mechanism studies. | View PPP5C Products |
| Gene Delivery | PPP5C Promise-ORF / Lentivirus for stable cell line construction. | View PPP5C Products |
| Validation Tools | Anti-PPP5C Control Antibody & siRNA Set for knockdown verification and assay standardization. | View PPP5C Products |
| Pathway Partner | HSP90AA1 – major interacting chaperone modulating PPP5C activation. | View HSP90AA1 Products |
| Selectivity Controls | Glucocorticoid Receptor (GR, downstream signaling) & PPP2CA (PP2A catalytic, counter-screening). | View GR Products / View PPP2CA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Allosteric Regulation / Autoinhibition Relief Studies | Full-length PPP5C with intact TPR domains; catalytic domain truncation variants available for activation mechanism studies. |
| Phosphatase Selectivity Screening | Homolog panel (PPP1C, PPP2CA, PPP3CA) with >95% purity for cross-reactivity assays. |
| Substrate/Co-factor Binding | Catalytic domain truncation variants for structural/functional mapping. |
| Cellular Validation & Specificity | Validated siRNA and benchmark antibodies to confirm target engagement and reduce false positives. |
Live PPP5C R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- Latest Resistance Research
- Latest Inhibitor Research
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for PPP5C therapeutics remains in early discovery and preclinical stages, led by academic institutions and specialized biotechs. PPP5C is a unique serine/threonine phosphatase with an N-terminal TPR domain, playing critical roles in cellular stress responses, DNA damage repair, and HSP90 client protein regulation. The next wave of R&D focuses on selective small molecule allosteric modulators that disrupt the autoinhibitory TPR-catalytic domain interaction, as well as PROTAC degraders to overcome active-site conservation across phosphatase families. Key indications include oncology (addressing therapy resistance) and neurodegeneration (Alzheimer's, Parkinson's).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors (Catalytic) | Academic Consortia, Early Biotechs | Solid Tumors, Alzheimer's | Enzyme Activity Assay (Need high-purity WT and mutant PPP5C) |
| Allosteric Modulators (TPR-targeted) | Preclinical Groups, Startups | Cancer (Breast, Prostate), Neurodegeneration | TPR-domain Binding Assay (Need full-length protein with intact TPR domains; SPR/BLI) |
| PROTAC Degraders | Emerging Startups | Refractory Tumors | Ternary Complex Formation (Need well-folded, pure recombinant PPP5C) |
| Peptide Therapeutics | Preclinical Groups | Metabolic Disorders, Inflammation | Protein-Protein Interaction Assays (SPR/BLI requiring monomeric PPP5C) |